Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,707 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequence 2 Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mindfulness for Anger in Veterans With PTSD

NCT02882802
View directory record Official record
Conditions
Anger, Aggression
Interventions
Mindfulness Based Stress Reduction, Trauma Recovery Education Class
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults

NCT07578636
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
Oral [14C] PF-07799544, Oral Unlabeled PF-07799544, IV [14C] PF-07799544
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

NCT04610671
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer
Interventions
CG0070, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

NCT06592339
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MK-0616
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

NCT01301092
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
LY2189265
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Not applicable Interventional Results available

Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide

NCT01478854
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Radiation, Chemotherapy
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

NCT05455502
View directory record Official record
Conditions
Pain
Interventions
VX-548
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

NCT02130531
View directory record Official record
Conditions
Geographic Atrophy, Age-Related Macular Degeneration
Interventions
Emixustat HCl Tablet, Placebo Tablet
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Not applicable Interventional

Evaluating Therapeutic Response to Novo-TTF

NCT02441322
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Novo-TTF
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Acute Intermittent Hypoxia on Sensory Function in Healthy Adults

NCT03283072
View directory record Official record
Conditions
Sensitivity
Interventions
Intervention 1, Intervention 2, Intervention 3, Intervention 4 (sham)
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

NCT06785454
View directory record Official record
Conditions
Obstructive Sleep Apnea, Hypertension
Interventions
Lorundrostat, Placebo
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
27
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

NCT01454622
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851095
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Not applicable Interventional

Remote Vinyasa Yoga Program for Heart Health

NCT06961981
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Vinyasa Yoga
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants

NCT05134337
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LOXO-305, Itraconazole, Rifampin
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

NCT02706834
View directory record Official record
Conditions
Dose Finding Study
Interventions
TAK-828, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Baltimore, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

NCT02581553
View directory record Official record
Conditions
Healthy
Interventions
lesinurad/allopurinol 200/300 FDC tablets, lesinurad 200 mg, allopurinol 300 mg, lesinurad/allopurinol 200/200 FDC tablets, allopurinol 200 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 2 Interventional

Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome

NCT06527937
View directory record Official record
Conditions
Allergic Reaction
Interventions
DESF, Epinephrine Injection
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 21, 2026, 3:23 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

NCT04875975
View directory record Official record
Conditions
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Interventions
Rozanolixizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants

NCT05994807
View directory record Official record
Conditions
Healthy Volunteers
Interventions
DC-806, Itraconazole, Carbamazepine
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 3:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Aging, Geriatric Syndromes and Clonal Hematopoiesis

NCT02604563
View directory record Official record
Conditions
Geriatrics, Aged, Geriatric Syndromes, Cardiovascular Diseases
Interventions
Cognitive Assessment, Activities of Daily Living Questionnaire, Instrumental Activities of Daily Living, subscale of the OARS, Karnofsky Self-reported Performance Rating Scale, Number of Falls, Physical Health Section, subscale of the OARS, MOS Social Activity Survey, Unintentional Weight Loss, Peripheral Blood Draw, Buccal Swab, Heart Health and Smoking History from BRFSS questionnaire, Gait Speed, Grip Strength, Height and Weight measurements, Blood pressure measurement, Optional bone marrow biopsy, Blood draw for trauma measurements, Femur head donation, Knee bone fragments, Bone marrow aspirate
Other · Genetic · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes

NCT00591006
View directory record Official record
Conditions
Healthy
Interventions
Phenytoin (brand name Dilantin), Hydrocortisone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

NCT06974565
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Quinidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 21, 2026, 3:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions

NCT01012687
View directory record Official record
Conditions
Essential Hypertension
Interventions
perindopril erbumine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 3:23 AM EDT